Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 1 to 20 of 4873

1.

Predicting 15-year prostate cancer specific mortality after radical prostatectomy.

Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, Feng Z, Wood DP, Eastham JA, Yossepowitch O, Rabah DM, Kattan MW, Yu C, Klein EA, Stephenson AJ.

J Urol. 2011 Mar;185(3):869-75. doi: 10.1016/j.juro.2010.10.057. Epub 2011 Jan 15.

2.

Nomograms for clinically localized prostate cancer. Part I: radical prostatectomy.

Han M, Partin AW.

Semin Urol Oncol. 2002 May;20(2):123-30.

PMID:
12012298
3.

A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria.

Gretzer MB, Trock BJ, Han M, Walsh PC.

J Urol. 2002 Oct;168(4 Pt 1):1419-22. Erratum in: J Urol 2002 Dec;168(6):2558.

PMID:
12352408
4.

Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.

Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC.

J Urol. 2003 Feb;169(2):517-23.

PMID:
12544300
5.

Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003.

Khan MA, Han M, Partin AW, Epstein JI, Walsh PC.

Urology. 2003 Jul;62(1):86-91; discussion 91-2.

PMID:
12837428
6.
7.
8.
9.

Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy.

Gonzalez CM, Roehl KA, Antenor JV, Blunt LW, Han M, Catalona WJ.

Urology. 2004 Oct;64(4):723-8.

PMID:
15491709
10.

Association of hemospermia with prostate cancer.

Han M, Brannigan RE, Antenor JA, Roehl KA, Catalona WJ.

J Urol. 2004 Dec;172(6 Pt 1):2189-92.

PMID:
15538229
11.

Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies.

Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona WJ.

J Urol. 2004 Dec;172(6 Pt 1):2227-31.

PMID:
15538237
12.

Should an isolated humeral lesion detected during prostate cancer metastatic survey be biopsied?

Kundu SD, Han M, Catalona WJ.

J Urol. 2004 Nov;172(5 Pt 1):1825-6. No abstract available.

PMID:
15540730
13.
14.
15.

The natural history of clinically localized prostate cancer.

Gann PH, Han M.

JAMA. 2005 May 4;293(17):2149-51. No abstract available.

PMID:
15870419
16.

Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease.

Antenor JA, Roehl KA, Eggener SE, Kundu SD, Han M, Catalona WJ.

Urology. 2005 Jul;66(1):156-60.

PMID:
15992903
17.

Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates.

Pazona JF, Han M, Hawkins SA, Roehl KA, Catalona WJ.

J Urol. 2005 Oct;174(4 Pt 1):1282-6.

PMID:
16145393
18.
19.

Pathological characteristics of prostate cancer detected through prostate specific antigen based screening.

Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JA, Yap RL, Catalona WJ.

J Urol. 2006 Mar;175(3 Pt 1):902-6.

PMID:
16469576
20.

Lymphovascular invasion in radical prostatectomy specimens: prediction of adverse pathologic features and biochemical progression.

Loeb S, Roehl KA, Yu X, Antenor JA, Han M, Gashti SN, Yang XJ, Catalona WJ.

Urology. 2006 Jul;68(1):99-103. Epub 2006 Jun 27.

PMID:
16806410

Supplemental Content

Support Center